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Abstract
Major salivary gland tumours are uncommon neoplasms of the head and neck. The increase of precise pre-operative
diagnosis is crucial for their correct management and the identification of molecular markers would surely improve the
required accuracy. In this study we performed a comparative proteomic analysis of fine needle aspiration fluids of the most
frequent benign neoplasms of major salivary glands, namely pleomorphic adenoma and Warthin’s tumour, in order to draw
their proteomic profiles and to point out their significant features. Thirty-five patients submitted to parotidectomy were
included in the study, 22 were identified to have pleomorphic adenoma and 14 Warthin’s tumour. Fine needle aspiration
samples were processed using a two-dimensional electrophoresis/mass spectrometry-based approach. A total of 26
differentially expressed proteins were identified. Ingenuity software was used to search the biological processes to which
these proteins belong and to construct potential networks. Intriguingly, all Warthin’s tumour up-regulated proteins such as
Ig gamma-1 chain C region, Ig kappa chain C region and Ig alpha-1 chain C region and S100A9 were correlated to
immunological and inflammatory diseases, while pleomorphic adenomas such as annexin A1, annexin A4, macrophage-
capping protein, apolipoprotein E and alpha crystalline B chain were associated with cell death, apoptosis and
tumorigenesis, showing different features of two benign tumours. Overall, our results shed new light on the potential
usefulness of a proteomic approach to study parotid tumours and in particular up regulated proteins are able to
discriminate two types of benign parotid lesions.
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Introduction
Major salivary gland tumours (MSGT) are uncommon
neoplasms of the head and neck corresponding to about 8% of
the cancers of the head and neck, and they can be malignant or
benign. Malignant MSGT account for about 7% of epithelial
cancers of the head and neck in the United States, with an annual
incidence of about 1 per 100,000 population and a similar
incidence is reported in Europe. Benign MSGT occur more
frequently, but the precise incidence is difficult to quantify as they
are obviously not included in cancer registry data [1].
The management of MSGT is based on clinical assessment,
radiologic investigation, and cytologic study of fine needle
aspiration biopsy (FNAB) specimens. FNAB is a relatively painless
procedure for rapid diagnosis, as the lesions are readily accessible
[2]. Nevertheless, since different studies indicate higher values of
specificity than sensitivity, parotid carcinomas are frequently
misdiagnosed as a benign process (false-negative) than benign
lesions are diagnosed as carcinomas (false-positive). A recent
retrospective study indicates that among the false-negative results,
5 out of 11 cases of the cytological misdiagnosis were Warthin’s
tumours (WT), while among the false-positive results WT,
pleomorphic adenomas (PA) and lymphoepithelial lesions were
the most common histological types [3]. Tryggvason and co-
authors [4] reported diagnosis of 1,128 salivary gland FNAB.
These diagnoses contained very few false-positives, while false-
negatives were more common especially for carcinoma ex-PA
which was interpreted as PA for all 6 cases of misdiagnosis.
Nagel and collaborators [5] underlined that PA is most
frequently confused in cytology with adenoid cystic carcinomas,
principally because adenoid cystic carcinomas and PA are
composed of the same cellular and extracellular elements.
Diagnosis of a pleomorphic carcinoma may be confused with a
mucoepidermoid carcinoma according to Stewart [6].
In cases of WT with predominance of the lymphoid component,
squamous cells and necrotic/mucoid debris, there can be a
significant diagnostic challenge because the squamous element, in
particular, is common to squamous cell carcinomas and muco-
epidermoid carcinomas [7]. Aspirates dominated by lymphoid
components can be indistinguishable from a reactive lymph node
or sialadenitis. WT can be misdiagnosed with lymphocyte-rich
acinic cell carcinoma [8].
The increase of the pre-operative diagnosis is crucial for the
correct management of such neoplasms, and, in that sense, the
identification of molecular markers would surely improve the
required accuracy. A more reliable diagnostic tool would help
distinguish parotid neoplasms from parotid lymphomas, avoiding
unnecessary surgery.
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The application of proteomic analysis to different biological
fluids has disclosed significant differences in concentration of
various proteins between normal and affected subjects, opening
the door to the identification of potential biomarkers useful in the
early diagnosis and treatment of the disease. At this time,
proteomic application in head and neck cancer are confined to
search potential markers in tissue [9,10], blood [11] and saliva
samples [12] but, to our knowledge, no studies are reported about
the application of proteomic analysis to fine needle aspiration
(FNA) fluid of the parotid tumour. Proteome analysis has been
shown to be a powerful tool for studying human diseases and for
identifying novel prognostic, diagnostic, and therapeutic markers.
This approach has been successfully used to determine proteomic
profile of human thyroid FNA [13] and successively to identify
thyroid cancer biomarkers [14].
In this paper, using a combination of two-dimensional electro-
phoresis (2-DE) and mass spectrometry (MS), the proteome profile of
FNA samples of WT parotid tumours with those of PA samples was
compared. The aim of our study is to explore the possibility of
performing a proteomic analysis on the most frequent benign
neoplasms of major salivary glands, namely PA and WT, to draw
their proteomic profile and to point out their most significant
features in order to improve FNA cytology accuracy in the pre-
operative assessment of such lesions. Differential expression of
proteins of interest has been validated by Western Blot (WB)
analysis.
Materials and Methods
Materials
Iodoacetamide, dithiothreitol (DTT), 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS), urea, thiourea,
glycerol, sodium dodecyl sulfate (SDS), tetramethylethylenedia-
mine (TEMED), ammonium persulfate, glycine and 30% acryl-
amide-N,N,N bisacrylamide were acquired from Applichem
(Germany). IPGs pH 3–10 NL, pharmalyte 3–10 and dry strip
cover fluid were purchased from GE Health Care Europe
(Uppsala, Sweden). Enhanced chemiluminescence (ECL) detection
system was purchased from PerkinElmer (MA, USA). Anti-
Selenium binding protein 1 (SBP1) was purchased from Sigma-
Aldrich (MO, USA); anti-protein S100-A9 was purchased from
Santa Cruz Biotechnology (CA, USA); anti-macrophage-capping
protein (CAPG) and anti-S-formylglutathione hydrolase (ESD)
were purchased from Novus Biologicals (CO, USA); anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), anti-An-
nexin A1 (ANXA1), anti-alpha crystalline B chain (CRYAB) and
anti-superoxide dismutase [Cu-Zn] (SOD1) were purchased from
Cell Signaling Technology, Inc. (MA, USA); anti-Ig gamma-1
chain C region (IGHG1) was purchased from Abnova (Taiwan).
Secondary antibodies (horseradish peroxidase (HRP)-conjugated)
were purchased from Stressgen (Belgium) (donkey anti-rabbit) and
from Santa Cruz Biotechnology (donkey anti-goat). All other
reagents were acquired from standard commercial sources and
were of the highest grade available.
Patients
Thirty-five patients submitted to parotidectomy were included
in the study (Table 1). Diagnostic results were obtained from
pathology reports that accompanied each specimen and were
confirmed after histological examination. The clinical profile and
tumour classification are summarised in Table 1.
Among the 36 patients, 22 were identified to have PA and 14
WT, the typical hystological images are shown in Figure 1. The
histopathological classification was performed in accordance with
the World Health Organization classification [15].
Ethics Statement
All patients gave their informed consent for proteomic studies.
This study was approved by the Local Ethics Committee
(Comitato per la sperimentazione clinica dei farmaci, Azienda
Ospedaliera Universitaria Pisana), and signed consent forms were
obtained for all patients.
Figure 1. Typical hystological image of PA and WT. The essential components of PA are the capsule, epithelial and myoepithelial cells and
mesenchimal or stromal elements. The epithelial component consists of a wide variety of cytologically bland cells, forming sheets or duct-like
structures. Ducts show a luminal layer of cuboidal cells and an abluminal layer of myoepithelial cells. The stromal mesenchimal-like component may
be myxoid, mucoid, cartilagineous or hyalinised (Haematoxylin & Eosin staining, magnification 4X) (panel A). The tumour is sharply demarcated with a
thin capsule, and is characterized by cystic and solid areas composed of lymphoid stroma and the epithelial component. The lymphoid stroma shows
varying degrees of reactivity and, usually, germinal centers. The epithelial component comprises two cell layers: the oncocytic luminal cells, tall and
columnar with palisading nuclei, and the flattened or cuboidal abluminal cells. Papillary structures usually project into the limina of cystic spaces
(Haematoxylin & Eosin staining, magnification 4X) (panel B).
doi:10.1371/journal.pone.0071874.g001
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Sample collection and preparation
Immediately after surgical removal of the parotid, a FNA was
made on the nodule. After passing the needle through the tissue 3
or 4 times, 1 mL of saline solution was aspirated with the same
syringe. This fluid was immediately centrifuged at 2300 g for
10 min at 4 uC The supernatants were stored at 280uC until use.
FNA proteins were precipitated with 1% of Trichloroacetic acid
containing 1 mM dithiothreitol (DTT). Protein pellets were washed
extensively with acetone at 0uC. The resulting pellets were
resuspended in rehydration solution (7 M Urea, 2 M thiourea, 4%
CHAPS, 60 mM DTT, 0.002% bromophenol blue) and incubated
for 30 min. at room temperature. After incubation, the samples were
centrifuged for 10 min at 14,000 g to remove undissolved material.
Protein concentrations were measured with a RC-DC Protein Assay
from Bio-Rad using bovine serum albumin as the standard. All
samples were stored at 280uC until analysis.
2-DE
Two pools belonging to the PA and WT samples were made
and each pool was submitted to 2-DE in triplicate. Isoelectrofo-
cusing (IEF) was carried out by using 18 cm Immobiline Dry-
Strips with a non-linear, pH 3–10, gradient. Two-hundred and
fifty mg of protein was filled to 350 ml of rehydration buffer
supplemented with 1% (v/v) pharmalyte, pH 3–10. IEF was
performed at 16uC on a Ettan IPGphor II apparatus (GE-
Healthcare) as previously described [13,16]. The second dimen-
sion was performed using the PROTEAN-II Multi Cell system
(Bio-Rad, CA, USA) on 12% polyacrylamide gel (18 cm x 20 cm x
1.5 mm) at 96 mA for 1 hour and at 192 mA for 15 hours
applying a continuous buffer system.
Staining and image analysis
The gels were stained with Ruthenium II tris (bathophenanthro-
line disulfonate) tetrasodium salt (SunaTech Inc) according to
Rabilloud and Lelong [17]. After electrophoresis, gels were fixed
for 1 hr. in 1% phosphoric acid (v/v, starting from commercial
85% phosphoric acid) and 30% ethanol; then gels were stained
overnight with 1 mM ruthenium complex (RuBP) in 1%
phosphoric acid–30% ethanol, destained for 4–6 hrs. in 1%
phosphoric acid–30% ethanol and rinsed in water (one rinse,
10 min) prior to imaging. The stained gels were acquired with on
fluorescence by ‘‘ImageQuant LAS4010’’ (GE-Healthcare), and
Table 1. Patients’ demographics and clinical features.
No Patients Gender F/M No Lesions
No Parotid Gland
(%)
No Submandibular gland
(%)
Dimensions (mm;
mean)
Range (mm; min-
max)
Total 36 15/11 37 35 (94.6) 2 (5.4) 25 9–50
WT 14 4/10 15 15 (100) 0 (0) 25 17–40
PA 22 11/11 22 20 (90.9) 2 (9.1) 24 9–50
WT: Warthin’s Tumor; PA: Pleomorphic Adenoma.
doi:10.1371/journal.pone.0071874.t001
Figure 2. Representative 2D gel maps of PA and WT FNA pool samples. A total of 250 mg of proteins was separated by 2D using an 18 cm
pH 3–10 NL strip and 12.5% SDS-PAGE. Proteins were detected by Ruthenium II tris (bathophenanthroline disulfonate) tetrasodium salt staining. The
maps were analyzed by Progenesis Same Spot (Nonlinear Dynamics) software. Spots numbers indicate all the proteins identified by MS/MS and refer
to the number reported in Table 2 (PA) and Table 3 (WT).
doi:10.1371/journal.pone.0071874.g002
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the images were analyzed with the Progenesis SameSpot (Non
linear - Dynamics) software as previously described [13]. The
software included statistical analysis calculations such as Anova p-
value and False Discovery Rate (q-values). A comparison between
PA and WT gels pool was performed. The protein spots with a
.2-fold spot quantity change between the two pools, p,0.05 and
q value ,0.05 were selected and identified (herein referred to as
‘‘differentially expressed proteins’’).
NanoLC-ESI-MS/MS analysis by LTQ-Orbitrap Velos
Analysis
Spots of interest were cut out from gel reference and the nanoLC-
ESI-MS/MS analysis by LTQ-Orbitrap Velos was performed as
previously described [16]. Peak lists were generated from raw
orbitrap data using the embedded software from the instrument
vendor (extract_MSN.exe). The monoisotopic masses of the selected
precursor ions were corrected using an in-house written Perl script.
The peak list files were searched against the SwissProt/trEMBL
database (Release 15.10 of 03-Nov-2009) using Mascot (Matrix
Sciences, London, UK). Human taxonomy (98529 sequences) was
specified for database searching. The parent ion tolerance was set to
10 ppm. Oxidation of methionine was specified in Mascot as a
variable modification. Trypsin was selected as the enzyme, with one
potential missed cleavage, and the normal cleavage mode was used.
The mascot search was validated using Scaffold 3.4.9 (Proteome
Software, Portland, OR). Only proteins matching with two different
peptides with a minimum probability score of 95% were considered
to be identified. The reference limit to p,0.05 for the probabilistic
scores of MS/MS assignment was 45. When multiple proteins were
Table 3. MS/MS data of protein spots up-regulated in WT FNA samples.
Spot
no. ID Protein name
Gene
name Th Obs
Matched
peptides
Coverage
(%)
Best ion
score Peptides identified FV p-value
MW/pI MW/pI
752 P02768 Serum albumin ALB 69/5.9 53/5.6 24 39 95.1 (K)AEFAEVSKLVTDLTK(V) 4.7 2.710e25
760 P02768 Serum albumin ALB 69/5.9 53/5.3 15 20 80.2 (K)LVAASQAALGL(-) 4.5 2.462e25
766 P02768 Serum albumin ALB 69/5.9 53/5.7 17 28 89.6 (K)LVAASQAALGL(-) 5.8 9.630e25
1057 P02675 Fibrinogen
beta chain
FGB 56/8.5 39/4.9 5 10 86.2 (K)LESDVSAQmEYcR(T) 2.1 2.447e24
1194 P02768 Serum albumin ALB 69/5.9 35/4.8 4 7 45.0 (R)FPKAEFAEVSK(L) 4.2 0.010
1200 P01876 Ig alpha-1 chain
C region
IGHA1 38/6.1 35/5.7 6 20 80.0 (K)TFTcTAAYPESK(T) 3.0 1.289e24
1435 P01857 Ig gamma-1
chain C
region
IGHG1 36/8.5 31/5.9 6 23 59.3 (K)TTPPVLDSDGSFFLYSK(L) 6.5 6.774e24
1476 P01834 Ig kappa chain
C region
IGKC 12/5.6 30/6.6 3 48 46.5 (K)VDNALQSGNSQESVTEQDSK(D) 3.8 0.002
1476 P60174 Triosephosphate
isomerase
TPI1 27/5.6 30/6.6 2 11 63.7 (K)QSLGELIGTLNAAK(V) 3.8 0.002
1511 P0CG05 Ig lambda-2
chain C
regions
IGLC2 11/6.9 29/5.2 3 18 74.5 (R)SYScQVTHEGSTVEK(T) 5.4 1.341e25
1523 P01834 Ig kappa chain
C region
IGKC 12/5.6 29/5.7 4 54 65.0 (-)TVAAPSVFIFPPSDEQLK(S) 3.6 1.924e24
1523 P0CG05 Ig lambda-2
chain C
regions
IGLC2 11/6.9 29/5.7 3 48 58.2 (R)SYScQVTHEGSTVEK(T) 3.6 1.924e24
1525 P01834 Ig kappa chain
C region
IGKC 12/5.6 29/5.6 5 67 74.4 (K)VDNALQSGNSQESVTEQDSK(D) 2.7 0.002
1525 P0CG05 Ig lambda-2
chain C
regions
IGLC2 11/6.9 29/5.6 2 30 60.8 (R)SYScQVTHEGSTVEK(T) 2.7 0.002
1525 P04792 Heat shock
protein
beta-1
HSPB1 23/6.0 29/5.6 2 13 60.7 (K)LATQSNEITIPVTFESR(A) 2.7 0.002
1549 P01834 Ig kappa chain
C region
IGKC 12/5.6 29/5.7 2 36 54.9 (-)TVAAPSVFIFPPSDEQLK(S) 3.7 1.259e24
1559 P01834 Ig kappa chain
C region
IGKC 12/5.6 28/6.3 2 35 50.8 (K)VDNALQSGNSQESVTEQDSK(D) 3.3 8.485e24
1959 P00738 Haptoglobin HP 45/6.1 22/4.9 4 11 69.5 (R)TEGDGVYTLNDK(K) 2.3 4.768e24
2565 P06702 Protein S100-A9 S100A9 13/5.7 13/5.3 4 32 43.8 (R)KDLQNFLK(K) 5.1 3.933e26
2627 P01834 Ig kappa chain
C region
IGKC 12/5.6 11/5.7 3 48 58.4 (K)VDNALQSGNSQESVTEQDSK(D) 5.5 0.004
Th: theoretical; Obs: observed; FV: fold variation.
doi:10.1371/journal.pone.0071874.t003
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Figure 3. WB validation of selected differentially expressed proteins. ANXA1, CAPG, CRYAB, ESD, GAPDH, IGHG1, SBP1, SOD, S100A9
different expression by immunoblot analysis. Conventional SDS gels were run with protein extracts from PA and WT FNA samples from all samples
using 12% resolving capacity. Thirty micrograms of total proteins were loaded into each lane for CAPG, CRYAB, ESD, GAPDH, SBP1, SOD, S100A9 WB,
while 10 mg were loaded for ANXA1 and IGHG1 WB. Proteins were transferred onto nitrocellulose membranes and incubated with specific antibodies
against the target proteins. Four lanes for PA and WT are shown for each antibody and densitometry of the blots is shown on the top. Statistically
significant differences were determined by the Student t test and the p values are indicated.
doi:10.1371/journal.pone.0071874.g003
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identified in a single spot, the proteins with the highest number of
peptides were considered as those corresponding to the spot.
Western blot analysis
For western blotting (WB), all FNA samples were processed to
validate different protein expressions found with 2DE analysis.
Aliquots of each FNA sample were mixed with a SDS sample
buffer (Laemmli solution). Amount of the samples (ranging from
10 to 60 mg of proteins) were run on 12% SDS-PAGE gels, and
transferred onto nitrocellulose membranes (0.2 mm) using a
voltage of 100 V for 30 min. (Mini vertical gel system, Biorad).
Non-specific binding was prevented by blocking the membranes
with 3% low fat dried milk, 0.2% (v/v) Tween 20 in PBS (10 mM
NaH2PO4, pH 7.4, 0.9% NaCl) (PBS/milk/Tween) for 1 hr. at
room temperature. After blocking, the membranes were incubated
with an appropriately diluted primary antibody in a blocking
buffer overnight at 4uC (1:200 dilution for anti-protein S100-A9;
1:500 dilution for anti-CAPG and anti-ESD; 1:1000 dilution for
anti-SBP1, anti-GAPDH, anti-ANXA1, anti-CRYAB and anti-
SOD1; 1:5000 dilution for anti-IGHG1). After four washes with
PBS/milk/Tween, the immunocomplexes were detected using a
peroxidase-labelled secondary antibody (donkey anti-rabbit
1:10000 dilution, donkey anti-goat 1:5000). Immunoblots were
developed using the ECL detection system. The chemiluminescent
images were acquired by LAS4010 (GE Health Care). For the
comparison of protein expression levels between PA and WT
samples, the antigen-specific bands were quantified using the
Image Quant-L (GE Health Care).
Statistical analysis
Statistical analysis of the two classes (PA and WA) of gels was
performed by Progenesis Same Spot (Nonlinear Dynamics). The
software included the following statistical analysis calculations:
Anova p-value, False Discovery Rate (q-values). Statistical
significant differences in the immunoreactive bands were calcu-
lated by the Student t test.
Signalling pathway analysis
Functional pathway and network analyses were generated using
the Ingenuity pathways analysis (IPA) software v14400082 (2012,
Ingenuity Systems, www.ingenuity.com). IPA identified the path-
ways from the IPA library of canonical pathways that were most
significant to the data set. Proteins that met the expression ratio with
a cut-off of.2.0, a p value cut-off of 0.05 for differential expression,
and that were associated with a canonical pathway in the Ingenuity
Pathways Knowledge Base, were considered for the analysis.
HUGO or Swiss-Prot accession numbers and official gene symbols
were inserted into the software along with the corresponding
Figure 4. IPA network analysis of WT up-regulated proteins. The network is associated with immunological and inflammatory disease. Solid
lines correspond to direct protein-to-protein interactions/regulations, dashed lines correspond to indirect interactions/regulations.
doi:10.1371/journal.pone.0071874.g004
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comparison ratios between the groups. The network proteins
associated with biological functions and/or diseases in the Ingenuity
Pathways Knowledge Base were considered for the analysis. These
networks were scored for the degree of relevance, with values .3
having a 99.9% confidence level of not being generated by random
chance alone. The genetic networks that were created describe
functional relationships between gene products based on known
associations in the literature.
Results
Proteomic analysis of PA and WT FNA
A comparative proteomic analysis was performed on PA and
WT FNA samples using 2-DE followed by nanoLC-ESIMS/ MS.
Typical 2D gel images of PA and WT FNA samples are shown in
Fig. 2. By computational 2D gel image comparison, a total of 34
proteins differentially expressed were found with a fold variation
major than 2. Differentially expressed protein spots were
subsequently subjected to nano LC-ESI-MS/MS analysis and
identified, leading to the identification of 26 different proteins. A
list of identified proteins, MW, pI, score and coverage values of
MS/MS, fold-change in expression levels and p values are shown
in Tables 2 (PA) and 3 (WT). Interestingly, several spots (with pI
and MW observed different from theoretical) for the same protein
were found for serum albumin (n. 752, 760, 766, 1194), for
fibrinogen beta chain (n. 777, 1057) suggesting the occurrence of
post translational modification which often are associated with
different pathological state as reported in type 1 diabetes [18].
Validation of differentially expressed proteins in PA and
WT FNA samples by WB analysis
WB analysis, using specific polyclonal antibodies, was used to
validate the expression changes of some of the proteins identified
by 2DE. A subset of 9 candidate proteins was selected for
validation by immunoassays; in particular, the different expression
of ANXA1, CAPG, CRYAB, ESD, GAPDH, S100A9, SOD1,
Figure 5. IPA network analysis of PA up-regulated proteins. The network is associated with cancer disease. Solid lines correspond to direct
protein-to-protein interactions/regulations, dashed lines correspond to indirect interactions/regulations.
doi:10.1371/journal.pone.0071874.g005
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SBP1 and IGHG1 was confirmed. All PA and WT FNA samples
were analysed. For each tested protein, the optical density of
specific immunoreactive band was determined and the resulting
mean values 6 SEM were compared (Fig. 3). From the
comparison of PA and WT FNA samples, an increase of
expression both of ANXA1 (p = 0.0119), CAPG (p = 0.0415),
CRYAB (p = 0.0498), ESD (p = 0.0434), GAPDH (p = 0.0427),
SOD (p = 0.0101), SBP1 (p = 0.0358) and of S100A9
(p = 0.00383), IGHG1 (p = 0.0060) was confirmed in PA and
WT samples, respectively.
Network construction for biological processes
The assignment of biological processes and the subsequent
construction of networks were done using the Ingenuity software.
All the proteins that had a .2.0-fold statistically significant change
in expression between PA and WT FNA were included in the
analysis. Each identified protein was converted to its gene and
mapped to its corresponding gene object in the IPA knowledge
base. Two networks with a score value of 27 (WT network) and 29
(PA network) were generated (Fig. 4 and 5). Genes or gene
products are represented as nodes, and the biological relationship
between two nodes is represented as an edge (line). IPA was
utilized to retrieve the known functions of each protein. WT
network with highest score shows 35 proteins containing 10 of the
up-regulated proteins. This network is associated with immuno-
logical and inflammatory disease. The diseases associated to this
analysis are immunological (p-value 1.42E-2 – 4.93E-2) and
inflammatory diseases (p-value 1.42E-2 – 4.93E-2). PA network
shows 35 proteins, 12 of them found to be up-regulated in PA
samples, that are associated with cancer disease (p-value 7.35E-6 –
4.56E-2).
Discussion
Among parotid neoplasms, misdiagnosis can occur, leading to
unnecessary surgical intervention. For instance, from literature
reports, it emerges that even if it is still a matter of debate, it can be
stated that the development of WT is related to the epithelial cells
of the heterotopic salivary gland in the intraparotid lymph nodes
[19]. A mixture of oncocytic epithelial fragments and lymphocytes
in a proteinaceous background is a typical FNA cytologic finding.
Despite these typical cytological features, however, the variegated
morphology may lead to an erroneous cytopathological interpre-
tation and can make it difficult to differentiate from benign and
malignant neoplasms. At present, no genetic or protein biomarkers
have been advanced to enhance the accuracy of parotid tumour
cytological examination. In previous studies we demonstrated the
applicability of FNA proteomics to examine thyroid tumours
[13,14]. Now, in this study, for the first time, we performed a
proteomic comparative analysis of WT and PA parotid FNA fluids
in order to define potential protein biomarkers able to improve
pre-operative diagnosis. Thirty-four differentially expressed pro-
tein spots, with a fold variation major than 2, were found. Among
them, 16 resulted up-regulated in WT with respect to PA, while a
down regulation was observed for the residual 18 proteins.
Identification by mass spectrometry led to the identification of 26
different proteins. IPA analysis, performed on 16 up-regulated WT
proteins, associated with ‘‘Humoral Immune Response, Protein
Synthesis, Connective Tissue Disorders’’ network with the Top
Bio Functions related to connective tissue disorders, immunolog-
ical and inflammatory diseases. As shown by IPA network,
changes of S100A9 protein expression levels are known in
literature to be associated with autoimmune systemic inflamma-
tory diseases such as rheumatoid arthritis [20] and diffuse systemic
sclerosis [21,22] while an increase of IGKC and IGHA1 proteins
was found in saliva belonging to non-Hodgkin’s lymphoma patient
in comparison with primary Sjo¨gren syndrome [23], directly
correlated to the lymphoproliferative process. This observation
agrees with previous studies showing that WT is characterized by a
strong immunologic reaction, indeed Daguci and co-workers have
reported the presence of B-cells (CD20), NK (CD56) and T (CD3),
including helper subtypes (CD4) and suppressor (CD8) in the
WT’s stroma, something similar to that of normal or reactive
lymph nodes. Moreover, there is a strong positivity towards
markers of lymphocyte proliferation (CD20cy and CD45RO) [24].
These histological and cytoarchitectural aspects are in line with the
proteomic profile emerged in our findings where many proteins
related to immune response were found. In particular, we
described the overexpression of IGHG1, IGKC, IGHA1 and
IgG chains probably directly or indirectly induced from some
inflammatory mediators such as tumour necrosis factor (TNF).
Conversely, the IPA network obtained from the analysis of PA up-
regulated proteins, associated to Lipid Metabolism, Small Mole-
cules Biochemistry, Molecular Transport, with the Top Bio
functions and diseases related to cell death and survival, free
radical scavenging, cancer and inflammatory disease. Fourteen of
these proteins were included in the network and are known to be
candidate biomarkers in several types of tumours, where are
involved in proliferation, invasiveness and apoptotic processes and
then synthesis of reactive oxygen species.
As far as CapG is concerned, a 3.0 fold variation in 2D gels
analysis and a 2.4 fold variation in WB analysis in PA vs WT
samples was observed. CapG was originally identified as the
protein that binds to the barbed end of acting filaments [25]. It
was found to be overexpressed in lung cancer [26], cholangio-
carcinoma [27], colorectal cancer [28], breast cancer [29], ovarian
cancer [30], oral cancer [31], pancreatic cancer [32] and in
nasopharyngeal carcinoma [33]. CapG appears to play an
important role in the process of metastasis by promoting the
invasiveness of tumour cells as reported in hepatocellular
carcinoma. Kimura [34] compared hepatocellular carcinoma with
and without vascular invasion and found that those with vascular
invasion showed markedly up-regulated expression of CapG.
Moreover, silencing of CapG reduced tumour invasion without
affecting the proliferation of the HCC cells.
With regards to CRYAB, different and sometimes opposite roles
are described in literature. Our results suggested a strong increase
of CRYAB in PA vs WT confirmed also by WB analysis. CRYAB
is a member of the small heat shock protein (sHSP) family, is
expressed in various tissues where it acts as a molecular chaperone,
maintains protein conformation and prevents protein aggregation.
This role is described in the cells at physiological levels of CRYAB.
In contrast, when overexpressed, it appears to prevent apoptosis
through the interaction with the common apoptotic protein
pathways [35].
Besides CRYAB, annexins (ANXA1 and ANXA4) and Apoli-
poprotein E (APOE) are known to have antiapoptotic function
acting by different mechanisms of action. In particular, annexins
play important roles in different tumours such as hepatocellular
carcinoma, adenocarcinoma of the breast and prostate and head
and neck squamous cell carcinoma, where alone/or synergistically
regulate apoptosis, carcinogenesis, migration and invasion of
tumour cells [36]. In our network, all above mentioned proteins
directly interact with TP53 protein. Prediction of the upstream
and downstream effects of activation and inhibition on other
network proteins, suggests that a simulation of TP53 activation
agrees with the observed increase of ANXA1, ANXA4, APOE.
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These observations are according with an imbalance of apoptotic
response as already observed in other adenomas [37].
Overall, our results shed new light on the potential usefulness of
a proteomic approach to study parotid tumours, and most
importantly they highlight as upregulated proteins from WT and
PA generate different networks respectively, with the first
correlated to inflammatory and immunity events and the second
to early tumorigenesis process such as apoptosis, cellular growth
and stress response. These different features might be useful in the
differential diagnosis of benign parotid tumours. In fact the
identification of new markers may improve the clinical work
allowing a more specific diagnosis and consequently, an appro-
priate clinical treatment of patients with salivary parotid lesions.
Last but not least these markers could overcome the limit of
cytology and could lead to an advantageous reduction of surgical
interventions.
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